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ABSTRACT 
 
 SUMO-targeted ubiquitin ligases (STUbLs) are a newly defined class of enzymes 
that attach ubiquitin to sumoylated substrates. STUbLs are conserved from yeast to 
humans and have been implicated in DNA repair, transcriptional regulation, and genome 
stability. Importantly, studies on STUbLs provide insight into the crosstalk between the 
SUMO and ubiquitin conjugation pathways. The budding yeast STUbL Slx5-Slx8 has 
few confirmed ubiquitylation substrates, but many more are believed to exist. For 
example, Slx5-Slx8 ubiquitylates the DNA damage repair protein Rad52 in vitro; in vivo, 
the transcriptional regulator Mot1 and the transcription factor MAT"2 appear to be 
promising substrates.  
Recently, we observed a novel colocalization between Slx5 and a septin protein, 
Cdc3, as well as a two-hybrid interaction between Slx5 and the SUMO E3 ligase Siz1. 
The goals of this study, therefore, were to determine whether Slx5-Slx8 can ubiquitylate 
these substrates in vitro and to investigate the role that sumoylation plays in STUbL 
targeting. Here, we report that Slx5 interacts with the SUMO E3 ligase Siz1 in in vitro 
ubiquitylation and pulldown assays and that SUMO2 chains are required for the 
ubiquitylation of a substrate by the human STUbL RNF4. 
 
INTRODUCTION 
Ubiquitin: A Post-translational Modification 
 Post-translational modifications perform significant regulatory roles in the cell 
and can take the form of chemical groups or small protein modifiers. For example, 
phosphorylation, or the covalent attachment of a phosphate group, is critical for many 
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signal transduction pathways affecting transcription (reviewed by Karin and Hunter, 
1995). Ubiquitin is another example of a common post-translational modification and is 
the founding member of the ubiquitin-like protein (Ubl) family (Kerscher et al., 2006). 
Ubls participate in regulating many cellular processes, including transcription, DNA 
repair, and cell cycle control, among others (Hochstrasser, 2009). At 76 amino acids in 
length, ubiquitin is one of only two chain-forming Ubls. Specifically, ubiquitin chains are 
known to earmark targets for degradation by the proteasome, a complex involved in 
protein quality control. First synthesized as inactive precursors, Ubls become active after 
their attachment site is exposed. The carboxyl group of the C-terminal diglycine motif 
comprises this attachment site, which predominantly targets lysine side chains on 
substrate proteins. Ubiquitin’s seven internal lysines – Lys6, 11, 27, 29, 33, 48, and 63 – 
enable it to form chains on targets (Peng et al., 2003). Conventionally, Lys48 chains 
uniquely flag ubiquitylation targets for degradation. However, there is evidence that 
Lys63 chains may also achieve this effect (Saeki et al., 2009).  
Ubiquitin conjugation to target proteins is executed by a specific enzyme cascade 
– an E1 activating enzyme, an E2 conjugating enzyme, and an E3 ligase (Kerscher et al., 
2006). Ubiquitin is attached to the E1 in an energy-dependent exchange and then passed 
to the E2, which subsequently uses the E3 as a bridge to access the target. To ensure that 
this process occurs in an orderly, step-wise fashion, the E2 can only bind the E1 or the E3 
at any one time (Eletr et al., 2005). Much of this pathway has been worked out in the 
budding yeast Saccharomyces cerevisiae. In this system, Uba1 is the only E1, whereas 
there are a handful of E2s – Ubc1-8, -10, -11, and Ubc13-Mms2. The RING (really 
interesting new gene) and HECT classes are the only two defined classes of E3 ligases. 
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Named for their RING domain, RING E3s and the similar U-box E3s simultaneously 
bind the E2 and the substrate. In contrast, HECT E3s conjugate ubiquitin to the target 
only after it has been transferred from the E2 to the E3. 
 
SUMO 
The other chain-forming Ubl is SUMO (small ubiquitin-like modifier), which is 
18% identical to ubiquitin. At 11 kDa, SUMO adds approximately 20 kDa to modified 
proteins on a SDS-PAGE gel (Johnson, 2004). More than 1,000 proteins have been 
identified as potential SUMO-conjugation (sumoylation) targets (Makhnevych et al., 
2009). However, despite the prevalence of targets, only about 1% of these target protein 
pools are actually sumoylated at any one time (Johnson, 2004). In contrast to ubiquitin, 
the conjugation of poly-SUMO chains to substrates does not flag them for degradation. 
Instead, sumoylation often changes a target’s conformation, activity, localization, or 
interactions with other proteins.  
SUMO modifies proteins both covalently and noncovalently (Kerscher, 2007). To 
attach to a substrate covalently, SUMO recognizes a consensus motif on the target: 
#KXE, where # is a hydrophobic amino acid, and X is any amino acid. The noncovalent 
interaction between SUMO and its targets is mediated by SUMO-interacting motifs, or 
SIMs (Kerscher, 2007).  While there are 16 ubiquitin-binding domains, only one SIM has 
been identified. Noncovalent modification by SUMO is especially important for proper 
PML (promyelocytic leukemia) body formation, for example; PML bodies are domains 
within the nucleus that recruit proteins involved in transcriptional regulation and DNA 
repair. Noncovalent sumoylation may explain why it appears that so few proteins are 
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covalently conjugated to SUMO. Importantly, the sumoylation pathway intersects with 
other post-translational modification pathways. For example, phosphorylation is typically 
considered to be antagonistic to SUMO. Likewise, SUMO and ubiquitin can compete for 
substrate lysines (Johnson, 2004). 
Three types of SUMO exist in vertebrates: SUMO1, 2, and 3. SUMO2 and 
SUMO3, which are 98% identical, harbor the #KXE consensus sequence and are capable 
of using this lysine to form chains (Ulrich, 2005). Therefore, the majority of free SUMO 
in the cell is in the form of SUMO2 or 3. On the other hand, only one type of SUMO 
exists in yeast – Smt3. Interestingly, smt3! can only be complemented by SUMO-1 
(Johnson and Hochstrasser, 1997). 
The SUMO conjugation pathway parallels that of ubiquitin but requires a 
different set of E1, E2, and E3 enzymes (Kerscher et al., 2006). First, Ulps make 
precursor SUMO conjugation-competent by freeing the C-terminal diglycine motif. 
These enzymes also cleave SUMO from substrates. Ulp1, for example, is a nuclear pore 
complex (NPC)- and bud neck-localized SUMO protease; deletion of this gene is lethal in 
yeast. While Ulp2/Smt4 doesn’t catalyze SUMO maturation, it is a nuclear protein with a 
more restricted set of desumoylation substrates; ulp2! strains exhibit stress-sensitivity 
and genome instability. In yeast, the E1 activating enzyme is the Aos1-Uba2 heterodimer. 
While the E2 enzyme, Ubc9, is sufficient to sumoylate substrates in vitro, the consensus 
is that sumoylation does occur through E3s even though they are nonessential in vitro 
(Schwarz et al., 1998, Kerscher et al., 2006). 
Sumoylation in budding yeast is executed by three E3 ligases – Siz1, Siz2, and 
Mms21. Siz1 and Siz2 belong to the Siz/PIAS (protein inhibitor of activated STAT) 
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family of SUMO E3 ligases and together carry out the vast majority of sumoylation in 
yeast cells (Reindle et al., 2006). PIAS family E3s contain SAP and SP-RING domains, 
the latter sharing similarity with the ubiquitin ligase RING domain (Hochstrasser, 2001). 
In vertebrates, a domain in the NPC protein RanBP2/Nup358 and a polycomb group 
protein Pc2, which belongs to a family of proteins involved in chromatin dynamics and 
gene silencing, both demonstrate SUMO E3 ligase activity (Pichler et al., 2002, Kagey et 
al., 2003). 
 
Crosstalk Between SUMO and Ubiquitin Systems 
Historically, there has been evidence for antagonism between the sumoylation and 
ubiquitylation pathways (Ulrich, 2005). For example, IkB$ activates the NFkB pathway 
upon its degradation, which is signaled by its phosphorylation and subsequent 
ubiquitylation (Karin and Ben-Neriah, 2000). Sumoylated IkB$, on the other hand, isn’t 
degraded, preventing the activation of NFkB (Desterro et al., 1998). Another example of 
antagonism between these two pathways occurs in the context of the Huntingtin protein, 
which is involved in Huntington’s disease. While sumoylation of Huntingtin stabilizes 
the protein and exacerbates neurodegeneration, ubiquitylation destabilizes the protein and 
decreases its toxicity (Steffan et al., 2004).  
However, cooperation between the SUMO and ubiquitin pathways is also evident. 
For example, following DNA damage, the IkB kinase regulatory subunit NEMO is first 
sumoylated and kept in the nucleus, where it is then phosphorylated, ubiquitylated, and 
finally degraded (Huang et al., 2003); this triggers the activation of the NFkB pathway. 
Especially interesting concerning the crosstalk between the SUMO and ubiquitin 
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pathways was the accumulation of simultaneously sumoylated and ubiquitylated proteins 
in the presence of proteasome inhibitors (Uzunova et al., 2008).  
 
Slx5-Slx8: A SUMO-targeted Ubiquitin Ligase 
The cooperative crosstalk between these two pathways has taken new directions 
with the discovery of a subclass of E3 ligases termed SUMO-targeted ubiquitin ligases 
(STUbLs), which attach ubiquitin to sumoylated targets. The yeast STUbL Slx5-Slx8 is 
comprised of two subunits, both of which contain RING domains (Xie et al., 2007). Slx5 
serves as the targeting subunit of the heterodimer, while Slx8 executes the ubiquitin 
ligase function. Slx5-Slx8 was originally isolated from a synthetic lethal screen with the 
DNA helicase Sgs1 (Mullen et al., 2001). Synthetic lethality was also observed between 
Slx5 and Slx8 and components of the sumoylation machinery, establishing the first 
evidence of Slx5-Slx8’s involvement with the SUMO pathway (Wang et al., 2006). 
Additionally, Slx5 was identified as a high-copy suppressor of a ulp1ts mutant (Xie et al., 
2007); at the nonpermissive temperature, the SUMO protease Ulp1 is nonfunctional and 
cannot cleave SUMO from substrates. The fact that Slx5 can rescue this mutant provided 
further evidence for a link between Slx5-Slx8 and the sumoylation pathway. 
Mutations in Slx5 and Slx8 confer elevated rates of gross chromosomal 
rearrangements (GCRs) and DNA damage, implicating roles for Slx5-Slx8 in resolving 
stalled replication forks and DNA damage repair (Zhang et al., 2006). In support of these 
roles, the DNA damage repair protein Rad52 was identified as the first in vitro substrate 
of Slx5-Slx8 (Xie et al., 2007). In vivo substrates include the transcriptional regulator 
Mot1 and the transcription factor MAT"2, which also serves as an in vitro target (Wang 
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and Prelich, 2009, Xie et al., 2010). Significantly, STUbLs are conserved from yeast to 
humans. Specifically, Slx5-Slx8’s human ortholog RNF4 has been shown to target the 
oncogenic fusion protein PML-RAR", which is involved in acute promyelocytic 
leukemia (APL) (Tatham et al., 2008). Arsenic trioxide serves as an effective therapeutic 
for this cancer by inducing the sumoylation of PML and its STUbL-mediated 
ubiquitylation. Insights into Slx5-Slx8, therefore, may shed light on RNF4 and its 
substrates. 
 
A Structure-Function Analysis of Slx5 
Recently, we and others demonstrated that Slx5 forms nuclear foci and localizes 
to sites of double-stranded DNA breaks (Nagai et al., 2008, Cook et al., 2009). In an 
attempt to understand how Slx5 is targeted to these nuclear foci, we performed a 
structure-function analysis of Slx5 (Westerbeck et al., manuscript in preparation). Six C-
terminal truncations of Slx5 were generated and their localization patterns analyzed by 
fluorescence microscopy. Interestingly, we observed that the Slx5(C4) construct localized 
to the bud neck of dividing yeast cells (Figure 1).  
 
Figure 1: Slx5(C4) localizes to the bud neck of dividing yeast cells. A  GFP-tagged, C-terminal 
truncation of wild-type Slx5(C4) (1-621) was generated. Localization of wild-type (WT) Slx5 and Slx5(C4) 
were compared by fluorescence microscopy. While WT Slx5 formed nuclear foci, C4 staining was present in 
the cytosol and at the bud neck. SIMs 1-4 indicate SUMO interacting motifs 1-4. Figure by Jason 
Westerbeck.
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Therefore, we hypothesized that Slx5 could be localizing to the septins, a class of 
GTP-binding proteins and a structural feature of the bud neck. While septins are absent in 
plants, they are highly conserved and are important for proper cytoskeleton organization 
(Spiliotis, 2010). In yeast, five septins – Cdc3, Cdc10, Cdc11, Cdc12, and Shs1/Sep7 – 
form hetero-oligomeric complexes that assemble into filaments and then into complex, 
higher order structures (Weirich et al., 2008). Of these, only Shs1 is nonessential. 
Investigation into this novel bud neck localization of Slx5 led to the observation that 
Slx5(C4) colocalized with the septin Cdc3 (Figure 2). 
 
 
 
Interestingly, septins are highly sumoylated during mitosis. The SUMO E3 ligase 
Siz2 was originally identified as a regulator of septin sumoylation (Johnson and Gupta, 
2001, Takahashi et al., 2001a). However, observations of wild-type septin sumoylation in 
siz2! cells led to the conclusion that Siz1 is primarily responsible for the sumoylation of 
the septins Cdc3, Cdc11, and Shs1/Sep7 (Johnson and Gupta, 2001, Takahashi et al., 
Figure 2: Slx5(C4) colocalizes with the septin Cdc3 at the bud neck. Slx5(C4) lacks the potential 
nuclear localization signal and exhibits diffuse cytoplasmic staining with enrichment at the bud neck, where 
it colocalizes with Cdc3. Figure by Cecilia Esteban.
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2003). Therefore, given the colocalization we observed and the highly sumoylated state 
of the septins during mitosis, we considered the septins to be promising candidate STUbL 
substrates and worthy of further investigation. 
We hypothesized that this potential interaction between Slx5 and Cdc3 may be 
involved in septin ring disassembly. Specifically, Slx5 may be executing the STUbL-
mediated ubiquitylation of Cdc3, triggering its degradation. Therefore, to assess the effect 
of Slx5 on the septins, whole-cell protein extracts were isolated from slx5! cells. If 
sumoylated Cdc3 were serving as a STUbL substrate, we would expect to see an 
enhancement of Cdc3 sumoylation in slx5! cells. Strikingly, however, decreased septin 
sumoylation was observed in slx5! cells compared to wild-type cells (Figure 3).  
 
 
 
We therefore concluded that Slx5 may be indirectly affecting the sumoylation 
state of the septins. Because Siz1 is known to sumoylate septins, we hypothesized that 
Figure 3: slx5! cells exhibit decreased levels of 
sumoylated septin species. Protein extracts were 
isolated from nocodazole-arrested slx5! and wild-type 
(WT) yeast cells in both the absence and presence of 
Smt3gg-FLAG. Smt3gg is a form of Smt3 that lacks the 
C-terminal diglycine motif and is therefore conjugation-
incompetent. PGK is shown as a loading control. Figure 
by Jason Westerbeck.
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there may be an interaction between Slx5 and Siz1. Indeed, we observed a strong two-
hybrid interaction between this STUbL subunit and SUMO E3 ligase (Figure 4). 
 
 
 
Significantly, we also observed a two-hybrid interaction between a mutant form of Slx5-
Slx8’s human ortholog, RNF4, and Siz1’s human ortholog, PIAS1. This suggests that the 
Slx5-Siz1 interaction is conserved and that further characterization of this interaction 
may have important implications for humans. 
 
Specific Aims 
The specific aims of this thesis are as follows: 
Figure 4: Slx5 and Siz1 interact in a yeast two-hybrid 
screen. The Slx5 binding domain (BD) and the Siz1 activation 
domain (AD) interact, enabling growth on both -Trp -Leu (-T-L) 
and -Ade (-A) plates. Additionally, a mutant form of Slx5's 
human ortholog RNF4 interacts with Siz1's human ortholog, 
PIAS1. YOK1221 served as a positive control. White dashes 
indicate untested combinations. Figure by Jason Westerbeck.
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1. To test candidate STUbL substrates in an in vitro ubiquitylation assay. We 
will test the hypothesis that the septins and Siz1 serve as substrates of the yeast 
STUbL Slx5-Slx8. 
2. To determine if these prospective targets physically interact with Slx5-Slx8. 
Specifically, we will test that hypothesis that if candidate substrates are 
ubiquitylated in vitro by Slx5-Slx8, they will also interact with Slx5 in an in vitro 
pulldown assay. 
3. To investigate the role of SUMO chains in STUbL targeting. SUMO chains 
will be linked to a putative STUbL target to test whether this modification can 
enhance ubiquitylation. 
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MATERIALS AND METHODS 
 Bacterial hosts and plasmid constructs – A complete list of bacterial hosts and 
constructs used in this study is available in Table 1. Protein overexpression for affinity 
purification was executed in BL21(DE3) cells (Stratagene) or *R cells (Sean Prigge, 
Johns Hopkins School of Public Health), which contain the chloramphenicol-resistant 
pRIL plasmid (BOK 473, BOK 579). 
Our in vivo sumoylation system consisted of two duet plasmids courtesy of James 
Wohlschlegel – pRSF-Duet-UBC9/SMT3 (BOK 470) and pACYC-Duet-UBA2/AOS1 
(BOK 471) (Wohlschlegel et al., 2006). pGEX-2TZ-CDC3 (BOK 476) and pGEX-2TZ-
CDC11 (BOK 477) served as sumoylation substrates in this in vivo sumoylation strain 
and were also obtained from James Wohlschlegel. His6- and T7-tagged Rad52-SUMO, 
which we purified as a positive control for our in vitro ubiquitylation assay, was 
expressed by pET21a-RAD52(K220R)-SUMO-His6 and was a gift from Mark 
Hochstrasser’s lab (Xie et al., 2007). Finally, we obtained an enzymatically active 
truncation of Siz1 – pT-77-SIZ1!440-His – from Yoshimitsu Takahashi through 
AddGene (BOK 591) (Takahashi et al., 2003); this construct was used to purify Siz1!440 
and clone SIZ1!440 into the pET-SUMO vector (Invitrogen) to create a Smt3-Siz1!440 
fusion. 
Cloning CDC3, CDC11, and SIZ1!440 into the pET-SUMO vector – Invitrogen’s 
Champion pET-SUMO Protein Expression System was used to generate His6-tagged 
SUMO fusion proteins. CDC3 (BOK 476), CDC11 (BOK 477), and SIZ1!440 (BOK 
591) were PCR-amplified with the following oligos: CDC3 – OOK 397 and OOK 398; 
CDC11 – OOK 395A and OOK 396A; SIZ1!440 – OOK 546 and OOK 547. After 
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ligating amplicons into the pre-gapped pET-SUMO vector, constructs were confirmed by 
restriction digest and sequencing with primers provided by Invitrogen. Plasmids were 
then transformed into BL21(DE3) cells or *R cells. 
Bacterial transformation with TSS (See Appendix) – His6-UBC4, MBP-SLX5, 
and MBP-SLX8 were transformed into BL21(DE3) cells using transformation and storage 
solution (TSS – 5% DMSO, 50 mM Mg
2+
, 10% PEG at pH 6.5) as described previously 
in Chung et al., 1989. TSS was also used to develop an in vivo sumoylation strain by 
individually transforming BOK 470, BOK 471, and either BOK 476 or BOK 477 into 
BL21(DE3) cells. 
Electroporation into *R cells – One µL of a 1:1,000 miniprep dilution was added 
to a 40 µL aliquot of *R cells in an electroporation cuvette (VWR), which was inserted 
into an electroporator (Eppendorf). Following electroporation at 1700 V, 200 µL of SOC 
(2% bacto-tryptone, 20 mM glucose, 2.5 mM KCl, 10 mM MgCl2, 10 mM MgSO4, 
10mM NaCl, 0.5% yeast extract) were added. These 241 µL were transferred to a 
microcentrifuge tube, rotated at 37°C for one hour, and plated on an LB plate containing 
the appropriate antibiotic. See Table 1 for each plasmid’s resistance gene. Carbenicillin 
was used at 60 %g/mL for ampicillin-resistant bacterial strains, kanamycin at 50 %g/mL, 
and chloramphenicol at 170 %g/mL. 
Induction of protein overexpression with IPTG (See Appendix) – One colony of 
BL21(DE3) or *R cells expressing the recombinant protein to be purified was inoculated 
in 4 mL of LB broth containing the appropriate antibiotic and grown up overnight by 
rotating at 37°C. This 4 mL culture was transferred to a flask containing 200 mL SOC 
and grown up at 37°C to OD600 0.3-0.4. A 1 mL sample of this uninduced culture was 
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collected and centrifuged. After discarding the supernatant, the cell pellet was 
resuspended in 60 µL of 1x LDS Sample Buffer (Invitrogen) containing BME (40 µL/1 
mL sample buffer). This sample was boiled in a 110°C heat block for three minutes and 
then frozen in liquid nitrogen. This was done a total of three times. 
After adding 80 µL of 1 M IPTG to the remaining 203 mL of bacterial culture, 
these cells were transferred to a 30°C shaker, where they were induced for 3.5 – 5 hours. 
Another 1 mL sample was collected as described above. To analyze protein induction, 
whole-cell protein extracts from uninduced and induced cell cultures were compared by 
running 10 µL of each 1 mL collection on a pre-cast NuPAGE Novex 4-12% Bis-Tris 
mini-gel (Invitrogen) for 55 minutes at 200 V in MOPS Buffer (Invitrogen). These gels 
were rinsed in distilled water, stained in either GelCode Blue (Pierce) or SimplyBlue Safe 
Stain (Invitrogen) for one hour, and destained in distilled water for another hour. Gels 
were placed on wet Whatman paper, covered with plastic wrap, and placed in a gel dryer 
for approximately 45 minutes at 80°C. The remainder of the cell culture was centrifuged 
at 4°C for 15 minutes at 5,000 RPM. After discarding the supernatant, cell pellets were 
kept on ice and gently resuspended by pipetting in 4 mL of 1x Halt Protease Inhibitor 
Cocktail (PI) (Thermo), diluted in 1x PBS. These 4 mL cultures were then spun down 
into screw-cap tubes and frozen in liquid nitrogen. 
Recombinant protein purification (See Appendix) – Frozen cell pellets of IPTG-
induced BL21(DE3) or *R cells were resuspended in 800 µL 1x Halt Protease Inhibitor 
Cocktail by pipetting. 1x PBS was then added to 2 mL. Cells were sonicated three times 
using a Branson sonifier. Sonicated cells were then centrifuged at 4 °C for 8 minutes at 
approximately 15,000 RPM. Protein extracts were added to a 15 mL conical and diluted 
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in 4 mL 1x PBS. Affinity columns (Pierce) were assembled per the manufacturer’s 
instructions. His6-tagged proteins (Ubc4, Smt3-Cdc3, Smt3-Cdc11, Siz1!440, and Smt3-
Siz1!440) were purified on Talon beads (Clontech), MBP-tagged proteins (Slx5, Slx8, 
and RNF4) on amylose resin (New England Biolabs), and GST-tagged proteins (Cdc3 
and Cdc11) on glutathione resin (GE). His6- and GST-tagged proteins were eluted with 
elution buffer (His6: USB; GST: BD Biosciences), and MBP-tagged proteins were eluted 
with 100 mM maltose. Glycerol was added to 15%. Elutions were then analyzed by gel 
staining as described previously. Proteins were frozen in liquid nitrogen and stored at -
80°C. 
In vitro ubiquitylation assay – For sizing and quantitation of enzymes and 
substrates used in our in vitro ubiquitylation assays, see Figure S2 and Table 2; these 
analyses were performed with a Protein 230 kit on the Agilent 2100 Bioanalyzer 
according to the manufacturer’s instructions. 10x ubiquitylation buffer, E1 enzyme 
(Uba1), ATP, and 20x ubiquitin were provided in a commercial ubiquitylation kit (Enzo). 
Ubiquitylation buffer, IPP (100 U/ml), DTT (50 µM), E1 (Uba1), E2 (Ubc4), and E3 
enzymes (Slx5-Slx8 or RNF4) were combined with purified substrate protein and 
ubiquitin. Reactions totaled 27 µL and were incubated in a 30°C heat block for three 
hours. Reactions were stopped by adding an equal volume of SUTEB sample buffer 
(0.01% bromophenol blue, 10 mM EDTA, 1% SDS, 50 mM Tris at pH 6.8, 8 M Urea) 
containing DTT (5 µL of 1 M DTT/1 mL SUTEB sample buffer). Protein products were 
boiled in a 65°C heat block for ten minutes, analyzed by Western blot as described 
below, frozen in liquid nitrogen, and stored at -80°C. 
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In vitro pulldown assay – MBP-Slx5, MBP-Slx8, and T7-Siz1!440 were 
overexpressed in BL21(DE3) or *R cells by IPTG induction as described above. Fifty 
ODs of cells overexpressing either MBP-Slx5 or MBP-Slx8 were each combined with 50 
ODs of cells overexpressing T7-Siz1!440. Fifty ODs of cells overexpressing T7-
Siz1!440 were also collected. Whole-cell protein extracts were then isolated and passed 
through a column containing amylose resin as described above (Recombinant protein 
purification). Proteins bound to the amylose resin were eluted with 1x LDS Sample 
Buffer (Invitrogen) and analyzed by Western blot as described below. 
Western blot – Proteins were separated on a pre-cast NuPAGE Novex 4-12% Bis-
Tris gel for 55 minutes at 200 V in 1x MOPS buffer. Proteins were then transferred to a 
polyvinylidene difluorine (PVDF) membrane (Millipore) by semi-dry transfer in semi-
dry transfer buffer (192 mM glycine, 250 mM Tris Acetate at pH 8.8, 20% methanol) for 
30 minutes at 19 V. The blot was blocked in TBS (150 mM NaCl, 50 mM Tris-HCl at pH 
7.4) containing 4% milk for an hour and then in 4% milk containing primary antibody 
overnight. "-Smt3R11B6 (Hochstrasser Lab, Yale), "-GST (Abcam), "-avidin-HRP 
(Pierce), "-T7 (Novagen), "-SUMO2 (Michael J. Matunis, JHSOM), and "-MBP (New 
England Biolabs) primary antibodies were used, all at a concentration of 1:10,000. After 
three, five-minute washes in large volumes of TBS containing TWEEN20 (1 mL 
TWEEN20/1 L TBS), blots were incubated in "-rabbit HRP (Abcam) or "-mouse HRP 
(GE) for 90 minutes and then washed again in large volumes of TBST three times for five 
minutes each. Chemiluminescent substrate (Millipore) was added to the blot, which was 
then wrapped in saran wrap and exposed to film. 
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RESULTS 
  
 Development of an in vitro ubiquitylation assay system to test candidate STUbL 
substrates – The yeast STUbL Slx5-Slx8 has only two confirmed ubiquitylation targets, 
the DNA damage repair protein Rad52 and the transcription factor MAT"2 (Xie et al., 
2007, Xie et al., 2010). The transcriptional regulator Mot1 is also a promising candidate 
(Wang and Prelich, 2009). However, many more substrates are believed to exist. We are 
very interested in identifying these potential targets and testing their efficacy to further 
our understanding of Slx5-Slx8’s role in genome stability. Therefore, we sought to 
develop an in vitro ubiquitylation assay for the analysis of prospective STUbL substrates.  
To determine whether Slx5-Slx8 could ubiquitylate a candidate target, we 
combined components of the ubiquitylation cascade: the E1 enzyme (Uba1), the E2 
enzyme (Ubc4), the E3 enzyme (the Slx5-Slx8 STUbL), the substrate protein in question, 
and ubiquitin (Figure 5A).  
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Several of these components were purified from bacteria, while others were provided in a 
commercial kit (See Materials & Methods). If Slx5-Slx8 ubiquitylated the candidate 
target, we would be able to observe ubiquitin-modified substrate proteins on a Western 
blot probed with an antibody to the substrate (Figure 5B). 
First, we affinity-purified His-Ubc4, MBP-Slx5, and MBP-Slx8 (Figure 6). To 
confirm the activity of the E2 enzyme, Ubc4, we took advantage of our observation that 
SUMO2 chains are efficient substrates of ubiquitylation by Slx5-Slx8’s human ortholog 
RNF4 (Figure S1). In tandem with this newly purified Ubc4, RNF4, also cloned and 
purified in our lab, ubiquitylated SUMO2 chains in vitro, confirming the activity of 
Ubc4. 
 
 
 
Identification of the septins as candidate STUbL substrates – As part of previous 
STUbL analysis, we observed an interesting mislocalization of Slx5 to the bud neck of 
dividing yeast cells (Westerbeck et al., manuscript in preparation). We then demonstrated 
Figure 6: Purification of His6-Ubc4, MBP-Slx5, and MBP-Slx8. Whole-cell extracts from BL21(DE3) cells 
overexpressing His6-Ubc4 (A), MBP-Slx5 (B), or MBP-Slx8 (B) were passed through affinity columns containing 
Talon beads (A) or amylose resin (B). Purified protein elutions were analyzed on a 4-12% Bis-Tris gel stained 
with GelCode Blue.
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the in vivo colocalization of Slx5 and Cdc3, one of several septin proteins. Septins are a 
class of proteins that form a structural feature of the bud neck and are among the most 
highly sumoylated proteins in the yeast cell during mitosis. Based on the colocalization 
we observed and on Slx5’s binding of sumoylated proteins, we considered septins to be 
promising STUbL substrates. 
In vivo sumoylation of septins as prospective STUbL targets – To test the efficacy 
of the septins Cdc3 and Cdc11 as STUbL substrates, we attempted to sumoylate septins 
in vivo and purify these septin-SUMO conjugates out of bacteria. First, we tried to 
sumoylate the septins in a bacterial host harboring all the components of the sumoylation 
machinery (Wohlschlegel et al., 2006) (Figure 7). A plasmid expressing a SUMO E3 
ligase was not included in this bacterial strain because Ubc9 has been shown to conjugate 
Smt3 to substrates directly (Schwarz et al., 1998). 
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Next, we expressed GST-tagged septin-SUMO conjugates in this bacterially 
reconstituted expression system as described previously. GST-Cdc3 and GST-Cdc11 
were then affinity-purified. Our analysis of the eluates by gel staining (Figure 8A) and by 
Western blot with "-GST and "-Smt3 antibodies (Figure 8B) suggested that we were 
successful in purifying both unsumoylated (~80 kDa) and sumoylated Cdc3 (~100 kDa). 
First, we observed a band at approximately 100 kDa in the second and third elutions of 
Cdc3. Second, the "-GST antibody detected the expected 20 kDa sumoylation shift 
between these two forms of Cdc3 (Johnson, 2004). Finally, both the "-GST and "-Smt3 
antibodies detected a band at approximately 100 kDa, the anticipated size of GST-Cdc3-
Smt3. 
 
 
 
On the other hand, we did not observe a band at the appropriate size for GST-
Cdc11 or GST-Cdc11-Smt3 on the stained gel (Figure 8A). However, according to the "-
GST blot, we were successful in purifying unmodified Cdc11 (Figure 8B, left). Given the 
absence of bands detected by the "-Smt3 antibody at the expected size for GST-Cdc11-
Figure 8: Purification of sumoylated septins from an in vivo sumoylation reconstitution system. A. Sumoylated 
septins were purified on glutathione resin by isolating whole-cell soluble protein extracts from BL21(DE3) cells containing 
our in vivo sumoylation reconstitution system and passing these extracts through an affinity column containing 
glutathione resin. Purified protein elutions of were analyzed on a 4-12% Bis-Tris gel stained with GelCode Blue. B. 
Purified GST-Cdc3-Smt3 (lane 1) and GST-Cdc11 (lane 2) were transferred from a 4-12% Bis-Tris gel to a PVDF 
membrane by semi-dry transfer and immunoblotted with anti-GST and anti-Smt3 antibodies.
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Smt3 conjugates, we concluded that Cdc11 did not exhibit the previously published 
sumoylation (Wohlschlegel et al., 2008). Because STUbL ubiquitylation activity is not 
always SUMO-dependent – for example, Slx5-Slx8 can ubiquitylate an unsumoylated 
form of the transcription factor MAT"2 in vivo (Xie et al., 2010) – we decided to proceed 
with testing Cdc3 and Cdc11 to determine whether Slx5-Slx8 could ubiquitylate septins 
in vitro.  
 Testing the septins in our in vitro STUbL assay – Purified GST-Cdc3-Smt3 and 
GST-Cdc11 were used in in vitro ubiquitylation reactions by combining them with E1 
(Uba1), E2 (His6-Ubc4) and E3 (MBP-Slx5 and MBP-Slx8) enzymes, ATP, and 
ubiquitin at 30°C. After three hours, we separated the proteins products on SDS-PAGE 
gels and performed a Western blot, using an "-GST antibody to probe for the GST-tagged 
septins and an "-avidin-HRP antibody to probe for ubiquitin. Unfortunately, after 
experimenting with several reaction conditions, we did not observe any ubiquitylation of 
the purified septins (Figure 9). We suspected that the bands on the "-avidin-HRP blot 
were simply due to the formation of free ubiquitin chains (Figure 9, right). 
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 Given the uncertainty surrounding the sumoylation state of the purified septins, 
we decided to purify His6-tagged SUMO-septin fusion proteins. Cdc3 and Cdc11 ORFs 
were each cloned into the pET-SUMO vector (BOK 548, BOK 550) and then 
transformed into BL21(DE3) cells. We overexpressed Smt3-His6-Cdc3 and Smt3-His6-
Cdc11 and affinity-purified these proteins (Figure 10).  
 
 
 
Newly purified SUMO-septin fusion proteins were added to our in vitro STUbL assay. 
Unfortunately, we failed to observe any modification of these SUMO-septin fusion 
proteins (Figure 11). Specifically, when all of the ubiquitylation reaction components 
were present, an upshift of Smt3-Cdc3 and Smt3-Cdc11 due to ubiquitylation did not 
emerge. While the "-Smt3 antibody detected one band slightly higher than Smt3-Cdc3, 
this band was also present in the negative controls. Therefore, we cannot claim that this 
band is a ubiquitylated species of sumoylated septin. 
Figure 10: Purification of SUMO-septin fusion proteins. Cdc3 and Cdc11 ORFs were cloned into the pET-SUMO 
vector and then transformed into BL21(DE3) cells. Following IPTG induction, whole-cell extracts were isolated and 
passed through columns containing His6-specific Talon beads. Smt3-Cdc3 (A) and Smt3-Cdc11 (B) elutions were 
analyzed on a 4-12% Bis-Tris gel stained with GelCode Blue.
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Slx5-Slx8 ubiquitylates Siz1!440 and SUMO-Siz1!440 in vitro – At this time, we 
began to examine other septin-associated proteins and evaluate their potential to serve as 
STUbL substrates. Specifically, we observed that levels of SUMO-modified septins were 
significantly decreased in slx5! cells, drawing our attention to the SUMO ligase Siz1 
(Westerbeck et al., manuscript in preparation). Siz1 sumoylates septins during mitosis 
and accounts for the vast majority of sumoylation in the yeast cell (Johnson and Gupta, 
2001, Takahashi et al., 2001a). Before we utilized Siz1 as a substrate protein in our in 
vitro STUbL assay, we affinity-purified Rad52-SUMO – a confirmed, in vitro target of 
Slx5 (Xie et al., 2007) – to use as a positive control (Figure 12A). We also purified an 
enzymatically active truncation of Siz1 (Siz1!440) as well a SUMO-Siz1 fusion protein. 
Figure 11: Attempt to ubiquitylate SUMO-septin fusion proteins by Slx5-Slx8. 
E1 (Uba1), E2 (Ubc4), and E3 (the Slx5-Slx8 STUbL) enzymes were incubated with 
a SUMO-septin fusion protein and ubiquitin for three hours at 30°C (lanes 6-7). 
Control reactions were also performed (lanes 1-5). Reactions products were 
analyzed by immunoblotting with an anti-Smt3 antibody.
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We then performed an in vitro ubiquitylation assay with Rad52-SUMO as a 
positive control and Siz1!440 and Smt3-Siz1!440 as experimental substrates. We 
observed a slower-migrating adduct and smear above Rad52-SUMO, signaling 
ubiquitylation of Rad52-SUMO and confirming its utility as a positive control (Figure 
13A). After substituting Siz1!440 as the substrate, the "-T7 antibody detected several, 
strong bands above Siz1!440, suggesting mono-, di-, and polyubiquitylation (Figure 
13B). Finally, we observed monoubiquitylation of Smt3-Siz1!440 (Figure 13C). 
Siz1 interacts with both Slx5 and Slx8 in an in vitro pulldown assay – After 
demonstrating ubiquitylation of Siz1!440 and Smt3-Siz1!440 by Slx5-Slx8 in an in vitro 
ubiquitylation assay, we decided to investigate whether Slx5 and Siz1 would interact in 
an in vitro pulldown assay. In order to accomplish this, we individually overexpressed 
MBP-Slx5, MBP-Slx8, and T7-Siz1!440-His6 in BL21(DE3) or *R cells (BOK 500, 
BOK 501, BOK 758). We then combined these cell cultures as depicted in Figure 14. 
Figure 12: Purification of Rad52-SUMO, Siz1!440, and Smt3-Siz1!440. A plasmid expressing Rad52-SUMO, 
Siz1!440, or Smt3-Siz1!440 was transformed into  *R cells. Proteins were overexpessed by IPTG induction and then 
affinity-purified from whole-cell soluble protein extracts on Talon beads. Elutions were analyzed on a 4-12% Bis-Tris gel 
stained with GelCode Blue. A. Rad52-SUMO elutions. B. Siz1!440 and Smt3-Siz1!440 elutions.
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After extracting all of the proteins from these new, combined bacterial cultures, 
we ran the protein extracts through a column containing amylose resin, which would bind 
the MBP-Slx5 and MBP-Slx8. After eluting the proteins bound to the beads and 
performing a Western blot by probing with an "-T7 antibody, we observed in vitro 
interaction of Siz1!440 with both MBP-Slx5 and MBP-Slx8 (Figure 15). As expected, 
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bands were absent in the Siz1!440 lane, demonstrating that Siz1!440 alone did not bind 
to the amylose resin and was not responsible for the interaction we observed. 
 
 
 
SUMO2 chains are necessary for in vitro ubiquitylation of substrates by the 
human STUbL RNF4 – After demonstrating Slx5-Siz1 binding in in vitro ubiquitylation 
and pulldown assays, we probed further into the targeting of STUbLs to their substrates. 
Specifically, we were curious to determine the role that SUMO chains play in the in vitro 
STUbL-mediated ubiquitylation of targets. Previously, we showed that SUMO2 chains 
are efficient substrates of ubiquitylation by RNF4 (Figure S1). For our studies on the role 
of SUMO2 chains in in vitro ubiquitylation, a graduate student in the lab, Zac Elmore, 
purified the substrate-interacting domain (SID) of the SUMO protease Ulp1 on amylose 
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beads (Figure 16A). Fused to MBP, this “U-tag” could bind, but not cleave, SUMO 
chains (Figure 16B). We performed our in vitro ubiquitylation assay as previously 
described with both Slx5-Slx8 and MBP-RNF4 as E3 enzymes and the U-tag with and 
without SUMO2 chains as substrates. We then used Western blotting and "-SUMO2 and 
"-MBP antibodies to analyze our reactions. 
 
 
 
The "-SUMO2 antibody revealed that RNF4, but not Slx5-Slx8, ubiquitylated the 
SUMO2 chains conjugated to the U-tag (Figure 17). Further, the "-MBP antibody 
suggested that only in the presence of SUMO2 chains is the MBP-U-tag ubiquitylated by 
RNF4. Perhaps the RNF4-specific ubiquitylation of the U-tag is due to species specificity 
between RNF4 and SUMO2 chains. Further experiments should clarify whether the MBP 
or the U-tag is being ubiquitylated and whether the stabilization of SUMO2 chains by the 
U-tag enables ubiquitylation of other, U-tag-associated substrates.  
Figure 16: MBP-U-tag binds, but does not cleave, SUMO chains and may 
stimulate STUbL targeting and subsequent ubiquitylation. A. MBP was 
fused to the U-tag, the substrate-interacting domain (SID) of the SUMO 
protease Ulp1. MBP-U-tag can bind, but not cleave, SUMO chains. Therefore, 
MBP-U-tag was incubated with SUMO2 chains, and MBP-U-tag-(SUMO2)n 
conjugates were purified on amylose beads. B. Because MPB-U-tag can bind, 
but not cleave, SUMO chains, B. MBP-U-tag-(SUMO2)n may be able to recruit 
STUbLs to ubiquitylate SUMO chains and/or substrate proteins.
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DISCUSSION 
In this study, we set out to test candidate STUbL substrates in an in vitro 
ubiquitylation assay. Prospective targets included two septins and a SUMO E3 ligase, 
Siz1. Of these, the yeast STUbL Slx5-Slx8 ubiquitylated Siz1 in vitro. We were also able 
to demonstrate the interaction between Slx5 and Siz1 in an in vitro pulldown assay. In an 
attempt to advance our understanding of the role of SUMO chains in STUbL targeting, 
we also showed that non-covalent association of a protein is sufficient for STUbL 
targeting to this substrate. 
Are septins targets of the yeast STUbL Slx5-Slx8? – In our in vitro STUbL assay, 
we observed the formation of free ubiquitin chains, confirming the enzymatic activity of 
Slx5 and Slx8. However, it is likely that the purified septins from our in vivo sumoylation 
reconstitution system were, in fact, not sumoylated at all. Specifically, the transiency of 
sumoylation may have rendered the purification of septin-SUMO conjugates difficult; 
with the exception of RanGAP1, only 1% of SUMO substrates in the cell are sumoylated 
at any one time (Johnson, 2004). Therefore, because STUbL-mediated ubiquitylation can 
be SUMO-dependent (Lallemand-Breitenbach et al., 2008), the unsumoylated state of the 
purified septins could have prevented them from serving as efficient substrates of 
ubiquitylation. In an attempt to eliminate uncertainty surrounding the sumoylation state 
of the septins, we purified SUMO-septin fusion proteins, but we did not observe 
ubiquitylation of these conjugates either. Altogether, our observations suggested that the 
septins may not be bona fide STUbL substrates. 
How does Siz1 interact with Slx5?  – The finding that levels of sumoylated septins 
are decreased in slx5! cells (Westerbeck et al., manuscript in preparation) prompted us to 
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consider the enzyme that sumoylates the septins – Siz1 – to be a prospective STUbL 
substrate. After observing a two-hybrid interaction between Slx5 and Siz1 and their 
human orthologs RNF4 and PIAS1, respectively, we decided to test Siz1 in our in vitro 
STUbL assay. Specifically, we tested an enzymatically active, C-terminal truncation of 
Siz1 – Siz1!440 [Siz1(1-464)]  (Takahashi et al., 2003). Indeed, we observed 
polyubiquitylation of Siz1!440 by Slx5-Slx8 as well as interaction between Siz1 and 
both Slx5 and Slx8 in an in vitro pulldown assay.  
Given the two-hybrid interaction between Slx5 and Siz1 and the ubiquitylation of 
Siz1 by Slx5 in vitro, interaction between these two proteins in our in vitro pulldown 
assay was expected. However, very unexpected was the interaction between Slx8 and 
Siz1, which may suggest a previously undescribed role for Slx8 in substrate selection and 
specificity. Conventionally, SUMO-interacting motifs (SIMs) facilitate the noncovalent 
interaction between STUbLs and their sumoylated substrates (Kerscher, 2007). Slx5, with 
its two SIMs, is therefore considered the targeting subunit of the heterodimer, while Slx8 
harbors ubiquitin ligase activity. However, considering that STUbL-mediated 
ubiquitylation can be SUMO-independent in vitro (Xie et al., 2007) and in vivo (Xie et 
al., 2010), it is entirely possible that Slx5 and Slx8 may both shoulder substrate selection 
responsibilities. Interestingly, fusion of Smt3 to Siz1!440 did not enhance Slx5-Slx8’s 
ubiquitylation activity, supporting the hypothesis that there may be domains apart from 
Slx5’s SIMs that are important for Slx5-Slx8’s targeting of Siz1. In fact, Siz1 contains a 
SP-RING domain, which exhibits similarity to the RING domain characteristic of 
ubiquitin E3 ligases (Hochstrasser, 2001). Given that Slx5 and Slx8’s RING domains are 
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essential for their dimerization, perhaps Slx8’s RING domain and Siz1’s SP-RING 
domain enable the novel interaction we observed (Mullet et al., 2001). 
The Slx5-Siz1 interaction may be physiologically relevant. – While wild-type Slx5 
does not localize to the bud neck under physiological conditions, this previously 
undescribed interaction between Slx5 and a septin-associated protein may be 
physiologically relevant. Given Siz1’s sumoylation of the septins during mitosis, we 
implicate Slx5 in the control of septin sumoylation through Siz1. Slx5 and Siz1 are both 
nuclear proteins, so their interaction is not entirely surprising. However, following Siz1’s 
phosphorylation during G2/M, Siz1 is exported from the nucleus to sumoylate the septins 
during mitosis (Johnson and Gupta, 2001, Takahashi et al., 2001a). Therefore, it has been 
proposed that septin sumoylation is controlled by Siz1 localization, perhaps specifically 
by phosphorylation (Johnson, 2004). While the karyopherin Msn5 appears to be an 
important factor in Siz1’s export, the initial export signal is unclear (Takahashi and 
Kikuchi, 2005, Makhnevych et al., 2007). 
Additionally, there has been speculation about a possible role for autosumoylation 
and subsequent ubiquitylation in Siz1’s export (Takahashi et al., 2008). Our data are in 
support of this paradigm, in which the Slx5-Siz1 interaction is important for controlling 
the proper sumoylation or ubiquitylation state of Siz1 to enable its export into the 
cytoplasm. In the absence of Slx5, hypersumoylation of Siz1 may prevent this export 
event. Alternatively, a lack of Slx5 may deplete the cellular pool of free SUMO, 
preventing proper septin sumoylation (Figure 18).  
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Ubiquitylation is known to be capable of altering a protein’s localization. 
Specifically, monoubiquitylation affects protein transport across the cell membrane and 
in the endocytic pathway as well as in the nuclear-cytoplasmic shuttling of tumor 
suppressors like p53 (Hicke and Dunn, 2003, Salmena and Pnadolfi, 2007). However, 
this paradigm doesn’t automatically exclude a role for phosphorylation in Siz1 
localization and septin sumoylation (Johnson and Gupta, 2001); it is possible that these 
two post-translational modifications may work in tandem to ensure Siz1’s proper 
localization.  
Why are there differences between the substrate ubiquitylation by Slx5-Slx8 and 
RNF4 in the presence of SUMO2 chains? – We confirmed previous observations that 
RNF4, but not Slx5-Slx8, ubiquitylates human SUMO2 chains in vitro. Perhaps this 
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could be explained by species-specific interactions between SUMO2 chains and RNF4. 
We could test this possibility by using Smt3 chains in our in vitro ubiquitylation assay.  
Interestingly, SUMO2 chains drastically enhanced the ubiquitylation of MBP-U-
tag in vitro. Repeating the in vitro ubiquitylation assay with a SUMO mutant that cannot 
form chains could shed light on differences between mono- and polysumoylation in 
STUbL targeting. While it is clear that ubiquitin was conjugated to both the SUMO2 
chains and the MBP-U-tag, additional experiments will clarify where the MBP or the U-
tag is being ubiquitylated. If the MPB is ubiquitylated, the U-tag could, in theory, 
sumoylate any substrate and serve as a powerful tool to further our understanding of 
sumoylation and its effect on substrates. 
In summary, our data support interaction between the yeast STUbL subunit Slx5 
and the SUMO E3 ligase Siz1. We hypothesize that the STUbL activity of Slx5-Slx8 may 
enable the ubiquitylation of autosumoylated Siz1 and its subsequent export into the 
cytoplasm to sumoylate the septins, ensuring proper cell division. This feedback loop 
may provide a previously unrealized pathway for the regulation of protein sumoylation in 
the cell. Furthermore, insights into Slx5’s function and interactors may have important 
implications for its human ortholog RNF4 and its role in genome stability. 
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SUPPLEMENTARY FIGURES 
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Table 1: Plasmids Used 
BOK Gene(s) Based On Description Reference 
470 Ubc9/Smt3 pRSF (KanR) SUMO E2/Yeast SUMO Wohlschlegel et al., 
2006 
471 Uba2/Aos1 pACYC (CmR) SUMO E1s Wohlschlegel et al., 
2006 
473 [BL21(DE3)s]  Stratagene Catalog 
#200131 
Stratagene 
476 GST-Cdc3 pGEX-2TZ (AmpR) - Wohlschlegel et al., 
2006 
477 GST-Cd11 pGEX-2TZ (AmpR) - Wohlschlegel et al., 
2006 
478 BL21(DE3)s + Uba2/Aos1 BOK 471 - This Study 
479 BL21(DE3)s + Ubc9/Smt3 + 
Uba2/Aos1 
BOK 470, 471 In vivo sumoylation strain This Study 
480 His6-HsUbc4 - Ubiquitin E2 - 
485 Ubc9/Smt3 + Uba2/Aos1 + GST-Cdc3 BOK 470, 471, 476 - This Study 
488 Ubc9/Smt3 + Uba2/Aos1 + GST-
Cdc11 
BOK 470, 471, 477 - This Study 
500 BL21(DE3)s + MBP-Slx5 - - This Study 
501 BL21(DE3)s + MBP-Slx8 - - This Study 
539 [*Rs] CmR - Xie et al., 2007 
548 Smt3-Cdc3 pET-SUMO (KanR) OOK 397, OOK 398 Kim Fryrear 
550 Smt3-Cdc11 pET-SUMO (KanR) OOK 395A, OOK 396A Kim Fryrear 
584 RAD52(K220R)-SUMO-His6 pET21a (AmpR)  Xie et al., 2007 
591 T7-Siz1!440-His pT-77 (AmpR) From AddGene Takahashi et al., 2003 
758 *Rs + T7-Siz1!440-His BOK 591  This Study 
759 *Rs + Smt3-T7-Siz1!440 pET-SUMO (KanR) OOK 546, OOK 547 This Study 
 
  
 
 Table 2: Purified Recombinant Proteins Used in In Vitro Ubiquitylation Assays 
Protein Elutio
n 
Size (kDa) Concentration 
(ng/µL) 
Volume 
(µL) 
Amount (ng) Source (Date) 
His6-Ubc4 - 19.0 148.1 5 740.5 K. Fryrear (April 2010) 
MBP-Slx5* 2 130 202.1 4.25 858.9 B. Matson (July 2009) 
MBP-Slx8* 2 90 338.9 1.5 508.4 B. Matson (July 2009) 
T7-Siz1!440 2 62.6 25.1 5 125.5 J. Holloman (June 2010) 
T7-Siz1!440 2 64.7 10.0 5 50.0 B. Matson (February 2011) 
Smt3-
Siz1!440 
2 93.4 6.2 5 30.1 B. Matson (February 2011) 
Rad52-SUMO 2 75 25.8 5 142.5 B. Matson (September 
2010) 
MBP-RNF4° - 74.9 41.5 2.5 103.75 K. Fryrear 
MBP-U-tag - 63.4 130.9 2.5 327.25 Z. Elmore (March 2011) 
MBP-U-tag + 
(SUMO2)
n
 
- 63.7 157.2 5.0 786 Z. Elmore (March 2011) 
 
* Size and concentration estimated by comparison to a protein ladder and BSA standards, respectively, on a SYPRO Ruby-
stained gel using the GE Storm 845 phosphoimager. 
° Concentration and volume of a 2 µM dilution (20 µL RNF4 stock/280 µL 1x PBS).
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Appendix: Protocols 
 
Bacterial Transformation with TSS 
1. Grow cells in LB containing the appropriate antibiotic to OD600 0.3-0.4. 
2. Add an equal volume of cold 2x TSS. 
2X TSS (at pH 6.5): 180 mL  2x LB 
   20 g   PEG 
    10 mL  DMSO 
   10 mL  1 M MgCl2 
3. Add 100 !L of plasmid DNA. 
4. Incubate for 30 minutes at 4°C. 
5. Add 900 !L LB or TSS containing 20 mM glucose. 
6. Rotate at 37°C for one hour. 
7. Plate. 
 
IPTG Induction of Protein Overexpression in BL21(DE3) or *R Cells  
 
1. Rotate one bacterial colony overnight at 37°C in 4 mL LB containing the appropriate 
antibiotic. 
2. Add these 4 mL of bacterial culture to 200 mL SOC. 
3. Grow in a 37°C water bath or shaker to OD600 0.3-0.4. 
4. Remove 1 mL of bacterial culture. 
a. Spin down. 
b. Discard supernatant. 
c. Add 60 !L of sample buffer + BME (40 µL/1 mL sample buffer). 
d. Boil in a 110°C heat block for 3 minutes and freeze in liquid nitrogen. 
e. Repeat (d) twice. 
5. Add 80 !L 1 M IPTG. 
6. Shift the 204 mL bacterial culture to a 30°C water bath or shaker and grow for 3.5 – 5 
hours. 
7. Remove 1 mL of bacterial culture and perform steps 4a-e. 
8. Spin down the remaining 202 mL at 4 °C for 15 minutes at 5,000 RPM. 
9. Keeping cells on ice, resuspend in 4 mL PBS + protease inhibitors (PI). 
10. Spin these 4 mL into screw-cap freezer tubes, and try to resuspend. 
11. Freeze cell pellets in liquid nitrogen. 
 
Recombinant Protein Purification 
 
1. Resuspend the frozen cell pellet in 800 µL PBS + PI by pipetting. 
2. Add PBS to 2 mL 
3. Sonicate: 3 times on 20% duty cycle for a total of 20 seconds each time, alternating 2 
seconds “ON,” 2 seconds “OFF.” 
4. Spin at top speed for 8 minutes at 4°C. 
5. Move supernatant to a 15 mL conical tube. 
6. Add 4 mL PBS. Mix gently by inverting several times. 
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7. Assemble column underwater by using the plunger provided with the affinity 
columns to push the disc to the bottom of the column. 
a. *Cut the tip of the column if necessary to draw liquid through the column. 
8. Wash disc 3 times with 5 mL PBS. 
9. Add beads to column. 
10. Wash beads 3 times with 5 mL PBS. 
11. Add diluted protein (in 4 mL PBS in 15 mL conical) to column. 
12. Wash proteins 3 times with 5 mL PBS. 
13. Elute 3 or 4 times with the appropriate elution buffer. 
14. Add glycerol to 15% and aliquot elutions. 
15. Freeze in liquid nitrogen. 
 
In vitro Ubiquitylation Reaction 
 
See Figure S2 and Table 2 for size and quantitation of purified recombinant proteins used 
in this assay. An example in vitro ubiquityation reaction is assembled as follows: 
 
1. Assemble a master mix: 
3x  
3.75 uL 10x buffer 
15 uL IPP (100 U/mL) 
1.5 uL 50 mM DTT 
3.75 uL E1 enzyme (Uba1) 
 
2. Add 8 uL of this 3x master mix to each reaction. 
3. To each reaction, add:   
 
1.25 uL ATP 
2.5 uL E2 enzyme (Ubc4) 
4.5 uL Slx5 
1.25 uL Slx8 
5 uL Substrate 
2 uL Ub 
 
Note: For each control reaction, replace the reaction component with an equivalent 
volume of 1x PBS. 
 
4. Incubate reactions at 30°C for three hours. 
5. Stop reaction with an equal volume of SUTEB buffer + DTT (5 uL 1 M DTT in 1 mL 
SUTEB buffer). 
6. Boil at 65°C for 10 minutes. 
7. Load approximately 12 uL of each reaction onto a pre-cast NuPAGE Novex 4-12% 
Bis-Tris gel (Invitrogen). 
8. Run for 55 minutes at 200 V in MOPS buffer. 
9. Cut PDVF membrane and wet in methanol. 
10. Rinse two blotting pads, PVDF membrane, and gel in semi-dry transfer buffer. 
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11. Assemble semi-dry transfer and run for 30 minutes at 19 V. 
12. Block in TBS containing 4% milk for one hour. 
13. Incubate in primary antibody overnight. 
14. Wash blot three times in TBST for five minutes each. 
15. Incubate blot in secondary antibody for 90 minutes. 
16. Wash blot three times in TBST for five minutes each. 
17. Add chemiluminescent substrate and expose to film. 
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